KRYS News and Press, Krystal Biotech Inc. From 03/02/23

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the&#...

Krystal Biotech press release ( NASDAQ: KRYS ): Q4 GAAP EPS of -$1.25 misses by $0.26 . Cash, cash equivalents, and investments totaled $383.8 million on December 31, 2022. For further details see: Krystal Biotech GAAP EPS of -$1.25 misses by $0.26

• B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical trials in dermatology, respiratory and aesthetics to initiat...

Summary I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter. I just am not sure if I should be buying Krystal Biotech at current prices, given certain issues I discuss. Krystal Biotech ( KRYS ) has ...

The European Commission (EC) granted orphan designation to Krystal Biotech's ( NASDAQ: KRYS ) gene therapy KB407 to treat cystic fibrosis (CF). KB407 is an investigational, redosable gene therapy aimed at correcting the underlying cause of cystic fibrosis by delivering two copies ...

PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the European Commission has granted orpha...

Krystal Biotech ( NASDAQ: KRYS ) said on Monday that the U.S. Food and Drug Administration (FDA) extended the review period by three months of its application seeking approval for its gene therapy B-VEC to treat patients with a type of skin disorder called dystrophic epidermolysi...

PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration (FDA) notified the Company that based on manufacturing information submitted to the Agency on De...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the pivotal Phase 3 (GEM-3)...